Resources
7 Results (showing 1 - 7)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 6/9/2021 (updated 4/10/2024)
Background: Racial/ethnic disparities in the use of opioids to treat pain disorders have been previously reported in the emergency department (ED). Further research is needed to better evaluate the impact race/ethnicity may have on the use of opioids in adolescents for the management of pain disorders in the ED.
Engagement in drug treatment following nonfatal overdose among people who inject drugs in Appalachia
Posted 6/2/2021 (updated 4/10/2024)
Immediately after experiencing a non-fatal overdose, many people who inject drugs (PWID) engage in harm-minimizing behavior change, including engagement in drug treatment. To inform the implementation of tailored interventions designed to facilitate drug treatment engagement in rural communities, we sought to identify correlates of starting any form of drug treatment after their most recent overdose among PWID who reside in a rural county in West Virginia.
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.
Posted 12/18/2023 (updated 3/28/2024)
This study looks at perinatal care for pregnant people with substance use disorders. Stigma and lack of access to treatment and recovery increases the risk for pregnant people. Results and suggestions from the study include the need to expand OUD treatment training, clarification on child welfare reporting rules, the need to include philanthropic investment, and more.
Posted 8/10/2022 (updated 3/27/2024)
Researchers looked at what happens in rural and urban emergency departments (EDs) when peer-based services are used for patients arriving with opioid use disorder (OUD). The study aimed to find gaps in knowledge for rural EDs and found five key differences from urban counterparts that presented a challenge. Among these was difficulty identifying community partners.
Posted 5/3/2022 (updated 3/27/2024)
Buprenorphine utilization is an effective treatment for opioid use disorder (OUD). Given the recent
increase in child maltreatment reports related to parental substance use, research should explore the correlation between buprenorphine treatment and child maltreatment–related outcomes.
Posted 7/28/2023 (updated 3/26/2024)
Researchers interviewed 20 individuals – clinicians, peer support specialists, cultural practitioners, and others familiar with OUD treatment – in a Minnesota tribal community. The Cascade of Care model measures the quality of outcomes at each stage of treatment, from diagnosis to long-term maintenance, and was first proposed in 1998 as an approach to care for HIV/AIDS.